MX2021001395A - Arni variante contra alfa-sinucleína. - Google Patents
Arni variante contra alfa-sinucleína.Info
- Publication number
- MX2021001395A MX2021001395A MX2021001395A MX2021001395A MX2021001395A MX 2021001395 A MX2021001395 A MX 2021001395A MX 2021001395 A MX2021001395 A MX 2021001395A MX 2021001395 A MX2021001395 A MX 2021001395A MX 2021001395 A MX2021001395 A MX 2021001395A
- Authority
- MX
- Mexico
- Prior art keywords
- synuclein
- rnai
- rnai against
- against alpha
- further provided
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/38—Vector systems having a special element relevant for transcription being a stuffer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/11—Protein-serine/threonine kinases (2.7.11)
- C12Y207/11001—Non-specific serine/threonine protein kinase (2.7.11.1), i.e. casein kinase or checkpoint kinase
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Virology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
En la presente se proporcionan moléculas de ARNi para tratar sinucleinopatías neurodegenerativas. En algunas modalidades, las moléculas de ARNi están dirigidas a la expresión de alfa-sinucleína (SNCA). En la presente se proporcionan además construcciones de expresión, vectores (p.ej., AAVr), células, partículas virales, y composiciones farmacéuticas que contienen el ARNi. En la presente se proporcionan además adicionalmente métodos y kits relacionados con el uso del ARNi, por ejemplo, para tratar sinucleinopatías neurodegenerativas que incluyen la enfermedad de Parkinson, atrofia multisistémica, y demencia con cuerpos de Lewy.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862714616P | 2018-08-03 | 2018-08-03 | |
PCT/US2019/044924 WO2020028816A1 (en) | 2018-08-03 | 2019-08-02 | Variant rnai against alpha-synuclein |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021001395A true MX2021001395A (es) | 2021-08-11 |
Family
ID=67587976
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021001395A MX2021001395A (es) | 2018-08-03 | 2019-08-02 | Arni variante contra alfa-sinucleína. |
Country Status (15)
Country | Link |
---|---|
US (1) | US20210309999A1 (es) |
EP (1) | EP3830265A1 (es) |
JP (1) | JP2021534814A (es) |
KR (1) | KR20210062627A (es) |
CN (1) | CN112805382A (es) |
AR (1) | AR114540A1 (es) |
AU (1) | AU2019314529A1 (es) |
BR (1) | BR112021001980A2 (es) |
CA (1) | CA3108526A1 (es) |
CO (1) | CO2021002637A2 (es) |
IL (1) | IL280581A (es) |
MX (1) | MX2021001395A (es) |
SG (1) | SG11202101072UA (es) |
TW (1) | TW202022116A (es) |
WO (1) | WO2020028816A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20200056428A (ko) * | 2017-09-22 | 2020-05-22 | 젠자임 코포레이션 | 변이체 RNAi |
US20210363524A1 (en) * | 2020-03-18 | 2021-11-25 | University Of Massachusetts | Oligonucleotides for snca modulation |
EP4359525A1 (en) * | 2021-06-21 | 2024-05-01 | uniQure biopharma B.V. | Gene constructs for silencing alpha-synuclein and uses thereof |
US20230365968A1 (en) * | 2022-04-06 | 2023-11-16 | Genzyme Corporation | Targeted gene therapy for dm-1 myotonic dystrophy |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998010088A1 (en) | 1996-09-06 | 1998-03-12 | Trustees Of The University Of Pennsylvania | An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase |
US6566118B1 (en) | 1997-09-05 | 2003-05-20 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
US6995006B2 (en) | 1997-09-05 | 2006-02-07 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
AU781958C (en) | 1999-08-09 | 2006-03-30 | Targeted Genetics Corporation | Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms intrastrand base pairs |
ES2256265T3 (es) | 2000-06-01 | 2006-07-16 | University Of North Carolina At Chapel Hill | Vectores de parvovirus duplicados. |
US20050137155A1 (en) * | 2001-05-18 | 2005-06-23 | Sirna Therapeutics, Inc. | RNA interference mediated treatment of Parkinson disease using short interfering nucleic acid (siNA) |
US6723551B2 (en) | 2001-11-09 | 2004-04-20 | The United States Of America As Represented By The Department Of Health And Human Services | Production of adeno-associated virus in insect cells |
NZ532635A (en) | 2001-11-13 | 2007-05-31 | Univ Pennsylvania | A method of identifying unknown adeno-associated virus (AAV) sequences and a kit for the method |
WO2006119432A2 (en) | 2005-04-29 | 2006-11-09 | The Government Of The U.S.A., As Rep. By The Sec., Dept. Of Health & Human Services | Isolation, cloning and characterization of new adeno-associated virus (aav) serotypes |
WO2007120542A2 (en) | 2006-03-30 | 2007-10-25 | The Board Of Trustees Of The Leland Stanford Junior University | Aav capsid library and aav capsid proteins |
DK2164967T3 (en) | 2007-05-31 | 2015-10-19 | Univ Iowa Res Found | Reduction of off-target rna interferenstoksicitet |
GB0816778D0 (en) * | 2008-09-12 | 2008-10-22 | Isis Innovation | Gene silencing |
DK2826860T3 (en) | 2010-04-23 | 2018-12-03 | Univ Massachusetts | CNS targeting AAV vectors and methods for their use |
WO2012027713A2 (en) * | 2010-08-26 | 2012-03-01 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibition of snca |
US8663624B2 (en) | 2010-10-06 | 2014-03-04 | The Regents Of The University Of California | Adeno-associated virus virions with variant capsid and methods of use thereof |
EP3521451A1 (en) * | 2010-11-17 | 2019-08-07 | Ionis Pharmaceuticals, Inc. | Modulation of alpha synuclein expression |
BR112013020734A2 (pt) | 2011-02-17 | 2017-06-13 | Univ Pennsylvania | composições e métodos para alterar a especificidade do tecido e aprimorar a transferência gênica mediada por aav9 |
HUE054768T2 (hu) | 2014-05-02 | 2021-09-28 | Genzyme Corp | AAV vektorok retina és CNS génterápiára |
AU2016219396B2 (en) * | 2015-02-10 | 2022-03-17 | Genzyme Corporation | Variant RNAi |
-
2019
- 2019-08-02 EP EP19752626.2A patent/EP3830265A1/en active Pending
- 2019-08-02 AR ARP190102204A patent/AR114540A1/es unknown
- 2019-08-02 AU AU2019314529A patent/AU2019314529A1/en active Pending
- 2019-08-02 BR BR112021001980-4A patent/BR112021001980A2/pt unknown
- 2019-08-02 CA CA3108526A patent/CA3108526A1/en active Pending
- 2019-08-02 US US17/265,489 patent/US20210309999A1/en active Pending
- 2019-08-02 WO PCT/US2019/044924 patent/WO2020028816A1/en unknown
- 2019-08-02 CN CN201980063972.6A patent/CN112805382A/zh active Pending
- 2019-08-02 JP JP2021529252A patent/JP2021534814A/ja active Pending
- 2019-08-02 KR KR1020217006255A patent/KR20210062627A/ko unknown
- 2019-08-02 TW TW108127564A patent/TW202022116A/zh unknown
- 2019-08-02 MX MX2021001395A patent/MX2021001395A/es unknown
- 2019-08-02 SG SG11202101072UA patent/SG11202101072UA/en unknown
-
2021
- 2021-02-02 IL IL280581A patent/IL280581A/en unknown
- 2021-02-26 CO CONC2021/0002637A patent/CO2021002637A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
WO2020028816A1 (en) | 2020-02-06 |
AR114540A1 (es) | 2020-09-16 |
CN112805382A (zh) | 2021-05-14 |
TW202022116A (zh) | 2020-06-16 |
US20210309999A1 (en) | 2021-10-07 |
IL280581A (en) | 2021-03-25 |
AU2019314529A1 (en) | 2021-03-25 |
KR20210062627A (ko) | 2021-05-31 |
CA3108526A1 (en) | 2020-02-06 |
EP3830265A1 (en) | 2021-06-09 |
CO2021002637A2 (es) | 2021-07-30 |
SG11202101072UA (en) | 2021-03-30 |
BR112021001980A2 (pt) | 2021-05-04 |
JP2021534814A (ja) | 2021-12-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021001395A (es) | Arni variante contra alfa-sinucleína. | |
WO2019006418A3 (en) | ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY | |
BR112021005769A2 (pt) | proteínas de ligação a dll3 e métodos de uso | |
MX2020012028A (es) | Metodos y composiciones para tratar el cancer. | |
WO2020252397A8 (en) | Small molecule proteolysis-targeting chimeras and methods of use thereof | |
ECSP20025070A (es) | Proteínas trispecificas y métodos de uso | |
CR20230030A (es) | Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b (divisional 2020-0441) | |
SA518391624B1 (ar) | Ror- منظمات جاما | |
BR112018068189A2 (pt) | proteínas de ligação induzíveis e métodos de uso | |
BR112017014551A2 (pt) | ?anticorpo, construção de ácido nucleico, vetor de expressão, célula hospedeira, composição, métodos para tratamento de uma doença, para produção de um anticorpo biespecífico e para detecção da possível ocorrência de reticulação entre células com expressão de cd3 e cd20 em uma amostra derivada de um paciente, uso de um anticorpo biespecífico, e, kit? | |
BR112016025263A2 (pt) | vetores de avv para terapia genética retiniana e do snc | |
WO2018115097A9 (en) | Ophthalmic composition for treatment of dry eye disease | |
WO2019084057A3 (en) | Compositions and methods for the depletion of cd117+ cells | |
PH12020550117A1 (en) | Variant rnai | |
MY195386A (en) | Aav Treatment Of Huntington's Disease | |
MX2019013151A (es) | Composiciones y metodos para expresar otoferlina. | |
WO2019084064A3 (en) | Compositions and methods for the depletion of cd117+ cells | |
MX2017013113A (es) | Anticuerpos anti-pacap y sus usos. | |
EP3943092A3 (en) | Compositions for use in inducing differentiation of human brown adipocyte progenitors | |
MX2019000047A (es) | Inhibidores peptídicos de la acumulación de alfa-sinucleína basados en estructuras. | |
BR112019004353A2 (pt) | métodos e vetores para tratar distúrbios do cns | |
MX2019015071A (es) | Composiciones y metodos para tratar tauopatias. | |
CR20200322A (es) | Anticuerpos de cadena pesada que se unen a cd22 | |
MX2019004001A (es) | Compuestos de 2-amino-n- (arilsulfinil)-acetamida como inhibidores de la aminoacil-arnt sintetasa bacteriana. | |
BR112017005235A2 (pt) | vetores virais adeno-associados para o tratamento de glaucoma de miocilina (myoc) |